18 reports

  • Vendor landscape

Develops a platform technology to treat autoimmune diseases.

  • Type 1 Diabetes
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Insulin Pumps Outlook Type I Diabetes: Type I diabetes is an autoimmune disease that destroys the insulin producing beta cells in the pancreas of the human body.

  • Insulin Delivery
  • Type 1 Diabetes
  • World
  • Market Size
  • Animas Corporation
  • 7.1.2.2 MARKET SEGMENTATION - BY LOCALIZED AUTOIMMUNE DISEASE- TYPE 1 DIABETES
  • Inflammatory Bowel disease Type 1 Diabetes Thyroid Others

Autoimmune Disease Diagnostics Market The global autoimmune disease diagnostics market is expected to reach USD XXmillion by 2022 from USD XXmillion in 2016. During this period, the CAGR is expected to reach around XX%. There is an increasing prevalence of autoimmune disorders such as type 1 diabetes in newborn babies coupled with...

  • Immunochemistry Test
  • Type 1 Diabetes
  • World
  • Market Size
  • Thermo Fisher Scientific, Inc.

A chronic autoimmune disease.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.

A chronic autoimmune disease.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

A chronic autoimmune disease.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

A chronic autoimmune disease.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

A chronic autoimmune disease.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • 5.1 BIBLIOGRAPHY

A chronic autoimmune disease.

  • Type 1 Diabetes
  • Canada
  • North America
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • PIPELINE BY MACROGENICS INC, H2 2017
  • SEP 23, 2010: TOLERX PRESENTS BASELINE DATA FROM DEFEND-1 STUDY AT EUROPEAN ASSOCIATION FOR STUDY OF DIABETES ANNUAL MEETING

The company will first be evaluating foralumab in two clinical indications: ##) graft vs host disease, and ##) ulcerative colitis, an inflammatory bowel disease.

  • Therapy
  • Type 1 Diabetes
  • United States
  • World
  • Product Initiative
  • RECOMBINANT PEPTIDE FOR AUTOIMMUNE DISEASES - DRUG PROFILE
  • BIRCHBIOMED INC

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2017, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape. Type...

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • World
  • Company

The company will first be evaluating foralumab in two clinical indications: ##) graft vs host disease, and ##) ulcerative colitis, an inflammatory bowel disease.

  • Glycoprotein
  • Type 1 Diabetes
  • World
  • Product Initiative
  • Xencor, Inc.
  • Small Molecule to Agonize AhR for Type 1 Diabetes and Graft Versus Host Disease - Drug Profile
  • Drug to Agonize Aryl Hydrocarbon Receptor for Rheumatoid Arthritis - Drug Profile

These cells are functional and suppress the development of experimental spontaneous autoimmune diseases.

  • Therapy
  • Type 1 Diabetes
  • World
  • Product Initiative
  • Shenogen Pharma Group

Currently the founder and CEO of Octave Bioscience, an early-stage diagnostics company focused on neurodegenerative diseases, Hagstrom previously served as president and CEO of Crescendo Bioscience, which concentrated on specialty diagnostics for autoimmune and inflammatory

  • Monoclonal Antibody
  • Type 1 Diabetes
  • United States
  • Company
  • GlobalData's company
  • Business Description
  • VENTURE FINANCING

T##D is a chronic autoimmune disease that must be managed throughout the day and night.

  • Diabetes
  • Healthcare
  • Pharmaceutical
  • Type 1 Diabetes
  • United States
  • 6 Key Events and History

Those include- LX##, an orally-delivered small molecule compound for the treatment of irritable Other Programs LX##, an orally-delivered small molecule compound for the of treatment bowel syndrome autoimmune disease topically-delivered small molecule compound for LX##, the of

  • Clinical Trial
  • Endocrine Disease
  • Pharmaceutical
  • Therapy
  • Type 1 Diabetes
  • TYPE 1 DIABETES (JUVENILE DIABETES) - PIPELINE BY ATLANTIC BIO SCI LLC, H2 2016
  • TYPE 1 DIABETES (JUVENILE DIABETES)

It develops and offers products and technologies for the treatment of autoimmune diseases.

  • Biotechnology
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Company
  • Product Initiative
  • PARTNERSHIPS
  • SFC FLUIDICS ENTERS INTO DEVELOPMENT PARTNERSHIP WITH JUVENILE DIABETES RESEARCH FOUNDATION

It also performs clinical trials and tolerance assay studies in transplantation, autoimmune diseases, and allergy and asthma.

  • Diabetes
  • Medical Device
  • Medical Equipment
  • Type 1 Diabetes
  • United States